Loss of SNAI2 in prostate cancer correlates with clinical response to androgen deprivation therapy

M Cmero; NJ Kurganovs; R Stuchbery; P McCoy; C Grima; A Ngyuen; K Chow; S Mangiola; G Macintyre; N Howard; M Kerger; P Dundee; P Ruljancich; D Clarke; J Grummet; JS Peters; AJ Costello; S Norden; A Ryan; P Parente; CM Hovens; NM Corcoran

Journal article

Loss of SNAI2 in prostate cancer correlates with clinical response to androgen deprivation therapy

M Cmero, NJ Kurganovs, R Stuchbery, P McCoy, C Grima, A Ngyuen, K Chow, S Mangiola, G Macintyre, N Howard, M Kerger, P Dundee, P Ruljancich, D Clarke, J Grummet, JS Peters, AJ Costello, S Norden, A Ryan, P Parente Show all

JCO Precision Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1200/PO.20.00337

Download PDF

Abstract

PURPOSE Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration through a number of well-characterized mechanisms; however, little is known about what determines the magnitude of response to short-term pathway inhibition. METHODS We evaluated a novel combination of AR-targeting therapies (degarelix, abiraterone, and bicalutamide) and noted that the objective patient response to therapy was highly variable. To investigate what was driving treatment resistance in poorly responding patients, as a secondary outcome ..

View full abstract

University of Melbourne Researchers

Marek Cmero Author

Stefano Mangiola Author

Anthony Costello Author

Christopher Hovens Author

Related Projects (1)

Investigation of the source of new testosterone production in prostate tumours that become resistant to existing hormonal (testosterone lowering and blocking) therapies

Prostate cancer is critically dependent upon continued testosterone stimulation, even when the disease becomes resistant to existing hormona..

Grants

Awarded by Victorian Cancer Agency

Funding Acknowledgements

Supported by an NHMRC project grant 1024081 (N.M.C., C.M.H., and A.J.C.) and a Victorian Cancer Agency Early Career Seeding grant 14010 (N.M.C.) with support from a federal grant to the Epworth Prostate Cancer Centre from the Australian Department of Health and Aging (A.J.C.). N.M.C. was supported by a David Bickart Clinician Researcher Fellowship from the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne and more recently by a Movember-Distinguished Gentleman's Ride Clinician Scientist Award through the Prostate Cancer Foundation of Australia's Research Program. M.C. was supported by the Cybec Urology Fellowship, N.J.K. was supported by a postgraduate scholarship from Australian Prostate Cancer Research, and M.K. was supported by a Carlo Veccari Fellowship.